Advertisement
The report also finds that as compared to one year ago, Merck/Kyorin'sSingulair has posted large gains in second-line patient share, from 18.3percent to 20.2 percent.
Advertisement
"Singulair's gain is even all the more impressive since all othermaintenance therapies have lost share at second-line," said Michael Malecki,Ph.D., analyst at Decision Resources. "We believe that Singulair's benign sideeffect profile attributed to its second-line growth."
GlaxoSmithKline's Advair, the market leader, faces new competition fromAstraZeneca's Symbicort, according to the report. Physicians now have to weighfamiliarity with Advair against the faster onset of action of Symbicort.Symbicort's faster onset and European labeling for use as acute therapyappears to be influencing U.S.-based physicians, who report they are likely toprescribe Symbicort for both acute and maintenance treatment of asthma.
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the mostextensive claims-based longitudinal patient-level data from PharMetrics(R) toprovide exceptional insight into physicians' prescribing trends and thefactors that drive therapy product choice, from diagnosis through multiplecourses of treatment, for a specific disease.
For each disease examined, Decision Resources' Treatment AlgorithmsInsight Series provides:
About Decision Resources
Decision Resources, Inc., (http://www.DecisionResources.com) is a worldleader in healthcare market research publications, advisory services, andconsulting designed to help clients shape strategy, allocate resources, andmaster their chosen markets.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.-- Qualitative diagnosis and referral patterns for the United States based on thought leader input and guideline recommendations. -- Quantitative treatment algorithms based on patient-level claims data -- Product share (class and specific compound level) within each line of therapy (1st, 2nd, 3rd line). -- Practicing physician opinion on why specific drugs are chosen for certain patient populations. -- Discussion of key drug combinations (including add versus switch patterns) by lines of therapy. -- Progression of therapy from key 1st line products (e.g., initial treatment w/ Lipitor to 2nd line, 3rd line; initial treatment with Zocor to 2nd line, 3rd line). -- Pathway to key therapies from previous therapies (e.g., how much Avandamet use is preceded by metformin, Avandia, or both as single products?). -- Qualitative analysis of 2-year forecast incorporating practicing physician sentiment towards upcoming launches, changes in reimbursement, etc.
SOURCE Decision Resources
